Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals

Authors

  • Manuela Berto Pucca University of São Paulo; Faculty of Medicine of Ribeirão Preto; Department of Biochemistry and Immunology; Molecular Immunopathology Laboratory
  • Thaís Barboza Bertolini University of São Paulo; Faculty of Medicine of Ribeirão Preto; Department of Biochemistry and Immunology; Molecular Immunopathology Laboratory
  • José Elpidio Barbosa University of São Paulo; Faculty of Medicine of Ribeirão Preto; Department of Biochemistry and Immunology; Molecular Immunopathology Laboratory
  • Simone Vasconcelos Ribeiro Galina University of São Paulo; School of Economics, Business Administration and Accountancy of Ribeirao Preto; Department of Business Administration
  • Geciane Silveira Porto University of São Paulo; School of Economics, Business Administration and Accountancy of Ribeirao Preto; Department of Business Administration

DOI:

https://doi.org/10.1590/S1984-82502011000100005

Keywords:

Monoclonal antibodies, Recombinant antibodies, scFv, Biopharmaceuticals

Abstract

Monoclonal antibodies represent the fastest growing class of biopharmaceutical products and have a host of applications in medical research, diagnosis, therapy, and basic science. The production of recombinant monoclonal antibodies has revolutionized the generation of immunoglobulins, and their use represents a strategic breakthrough, affecting the global pharmaceutical market for therapeutic proteins. In the present work, a review of scFv, and the number of related patents, has been carried out. The results show that several countries have scFv patents, most notably the United States, China and United Kingdom. The target of these scFv antibodies was also assessed and the results demonstrate that most are directed toward cancer therapy.

Downloads

Download data is not yet available.

Downloads

Published

2011-03-01

Issue

Vol. 47 No. 1 (2011)

Section

Articles

License

All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.

The on line journal has open and free access.

How to Cite

Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals . (2011). Brazilian Journal of Pharmaceutical Sciences, 47(1), 31-38. https://doi.org/10.1590/S1984-82502011000100005